An interventional study of Angiolite stent in Coronary Heart Disease, sponsored by Josep Rodes-Cabau. Completed at 4 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-07-17.
Sponsored by Josep Rodes-Cabau · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Coronary Disease with a site in Spain — 5 open to participants now, 13 under way, none of them phase 3. Coronary Disease · Spain.
Among the 54 studies in Coronary Disease with a site in Spain, this one is the 32nd largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2015, is one of 22 with no phase, and was the 31st registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →5 of the 54 studies in Coronary Disease with a site in Spain are open now. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
Fundación EPIC · Sites in Spain
Ages 18+
Eva Rumiz González · Sites in Spain
Ages 18+
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · Sites in Spain
Ages 70+
Universidad Miguel Hernandez de Elche · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 160 across 780 interventional studies indexed under Coronary Disease.
Median enrollment 312 across the 42 interventional studies, 502 across the 12 observational. Of the 35 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 54 have an industry lead sponsor. The 10 most frequent:
Josep Rodes-Cabau is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Josep Rodes-Cabau has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Coronary Disease with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06273293Fundación EPICPostprocedural Contrast Mediated FFR Plus Intracoronary Infusion of Nitroglycerin in Multivessel Patients (PROMETEUS TRIAL) | 2026-12-20 |
| NCT06736899Fundación EPICTrial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions | 2026-12-31 |
| NCT06621524OrbusNeichEucaLimus Post-Market Registry | 2027-01 |
| NCT05027984Centro per la Lotta Contro l'Infarto - Fondazione OnlusInterventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS | 2027-01-31 |
| NCT06678490OrbusNeichSupport C Post-Market Registry | 2027-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Coronary Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to perform a first-in-man assessment of feasibility, exploratory efficacy and clinical performance of the novel Angiolite drug-eluting stent (iVascular, Barcelona, Spain) utilizing intracoronary optical coherence tomography (OCT).
This is a prospective registry including patient scheduled for a clinically-indicated percutaneous coronary intervention (PCI) of a de novo epicardial lesion with indication for drug-eluting stent implantation. Following study enrolment and PCI/stent with the Angiolite DES, patients will be scheduled for follow-up surveillance coronary angiography and OCT with the C7-XRTM Fourier Domain OCT system with C7 DragonflyTM catheter (St Jude Medical, Minneapolis, MN) or with the Terumo LunawayTM OCT system with fastview catheter (Terumo Medical Corporation, Tokyo, Japan). An adaptive design component of the study will randomize patients to either 3-month or 6-month angio/OCT follow-up. Clinical follow-up will occur at 30 days, 3 months, 6 months, 12 months and 24 months post PCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 3-month post index PCI.
Device: Angiolite stent
Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
Device: Angiolite stent
Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
Also known as: (Angiolite CE Mark reference number: 2014 12 0833 ED)
Neo-intimal coverage
Strut-based analysis: % of covered struts. Cross-sectional analysis: number of cross-sections with RUTTS (Rate of uncovered to total number of struts) score\>30%. Measured by an independant OCT laboratory
Time frame: 6-month
Neo-intimal obstruction
Strut-based analysis: mean neointimal thickness (µm). Cross-sectional analysis: neointimal volume obstruction (%). Measured by an independant OCT laboratory
Time frame: 6-month
Neo-intimal coverage
Strut-based analysis: % of covered struts. Cross-sectional analysis: number of cross-sections with RUTTS (Rate of uncovered to total number of struts) score\>30%. Measured by an independant OCT laboratory.
Time frame: 3-month
Neo-intimal obstruction
Strut-based analysis: mean neointimal thickness (µm). Cross-sectional analysis: neointimal volume obstruction (%). Measured by an independant OCT laboratory.
Time frame: 3-month
Apposition
Strut-based analysis: incomplete strut apposition (ISA) rate. Cross-sectional analysis: % frames with ISA. Measured by an independant OCT laboratory.
Time frame: 3- and 6-month
In-stent angiographic late lumen in mm
Confirmed by Imaging and measured by an independant QCA laboratory
Time frame: 6-month
In-stent and in-segment restenosis
Confirmed by Imaging and measured by an independant QCA laboratory (Reduction in percent diameter stenosis of stented segment of \>= 50%
Time frame: 6-month
CV death
Death from any known cardiovascular etiology
Time frame: 6-month and 1-year
Myocardial infarction
Peri-procedural myocardial infarction will be defined according to the 3rd universal definition of MI Following PCI, myocardial infarction will be defined according to the specific clinical situation of the patient.
Time frame: Peri-procedural, spontaneous
Target-lesion revascularization
Any repeat revascularization du to a restenosis within the DES-treated segment
Time frame: 24 months
Binary restenosis
Reduction in percent diameter stenosis of stented segment of \< vs.\>= 50%
Time frame: 24 months
Plan to share: Undecided
The record gives a start of May 2015, a primary completion of Jun 2017 and a completion of Jun 2018. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Josep Rodes-Cabau